Welcome to the ANTIFREAZE-F trial website
The Anti-Freaze-F trial is looking at the feasibility of conducting a large randomised controlled trial to assess whether an intra-articular injection of anti-TNF (Adalimumab) can reduce pain and improve function in people with pain predominant early-stage frozen shoulder.
We aim to recruit 84 men and women from across England with early stage Frozen shoulder (usually within the first 3 months of experiencing symptoms).
Frozen shoulder (adhesive capsulitis) is extremely painful and debilitating, affecting a person’s ability to perform daily tasks and sleep. It occurs when the capsule surrounding the shoulder joint becomes inflamed, thickened and tight.
It presents in three over-lapping phases: i) early painful inflammatory stage (lasts 3-9 months); ii) increased stiffness and impaired function (4-12 months); iii) final thawing phase (12-48 months).
August 2022:
Third site open to recruitment is Sandwell and West Birmingham NHS Trust
July 2022:
First participant recruited at University Hospitals Birmingham
May 2022:
First site to open to recruitment is United Lincolnshire Hospitals
Seocnd site to open to recruitment is University Hospitals Birmingham
January 2022:
The Anti-Freaze-F Trial received REC, MHRA and HRA Approvals in December 2021.
